AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentationat the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on 1 June 2015.
Over 80% of patients progression free at 9 months in the first-line treatment of advanced non-small cell lung cancer1
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC). Data showed that 81% (95% confidence interval (CI) 68% to 89%) of p
AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
Overall, data indicated clinical activity with manageable safety profiles for the anti-programmed cell death ligand 1 (PD-L1) monoclonal
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination as
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
AstraZeneca meddelar i dag sina planer på att investera cirka 285 miljoner USD i en ny högteknologisk anläggning för tillverkning av biologiska läkemedel i Gärtuna utanför Södertälje. Den nya anläggningen kommer fokusera på fyllning och packning av proteinläkemedel. Det förväntas att den nya enheten kommer att producera läkemedel till kliniska prövningsprogram för AstraZeneca och Medimmune, koncer
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015
AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab.
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.
Idag tilldelas Leg.läk. Professor Rolf Lewensohn, verksam vid Karolinska Institutet och Överläkare vid Onkologiska kliniken Karolinska Universitetssjukhuset i Stockholm, SLUSG-stipendiet 2015.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plu
Encouraging new data of relevance to Global public health crisis, presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Det finansiella resultatet för kvartal 1 2015 ger stöd åt upprepad helårsprognos för 2015.
oTotala intäkter (definierat som produktförsäljning och intäkter från externa samarbeten1) ökade med 1% i fasta valutakurser 2 (CER) till 6 057 MUSD (Q1 2014: 6 460 MUSD)
oVinst per aktie för kärnverksamheten (Core EPS) minskade med 3% till1,08 USD i takt med att vi fortsätter att investera i att uppn
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody
Idag tilldelas Berglind Libungans, verksam vid enheten för kardiologi, Sahlgrenska Universitetssjukhuset i Göteborg ett forskningsstipendium på 120 000 kr.
AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme
Uppdaterade data som presenterades vid European Lung Cancer Conference 2015 visar en fördröjning av tumörprogression på över ett år
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.